Related Experiment Video
Updated: Jan 10, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Optimization of velocity receptor transduction in CAR T cells
Xinyun Jiang1, Vasco Queiroga1,2, Eban A Hanna1,2
1Institute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.
Abstract:
Limited infiltration capacity significantly limits the effectiveness of chimeric antigen receptor (CAR) T cells for solid tumors. We have recently developed a large family of highly modular synthetic cytokine receptors termed velocity receptors (VRs), capable of binding key inflammatory cytokines, such as IL5, IL8, and TNFα, which drive CAR T cells into an elevated motility state. These new CAR T cells sense and amplify these autocrine secreted cytokines, thereby maintaining a self-propelled, high migratory state, facilitating penetration into dense tumor cores. In this study, we systematically evaluated key factors influencing VR transduction in order to improve their stable integration and expression. We established a dual-fluorescence reporter system to allow simultaneous monitoring of both VR and CAR constructs, and while evaluating modifications to the vector construct and generating standardized infectious unit (IFU) curves under various conditions. Our results demonstrate that the attempt to reduce overall lentiviral vector size by eliminating non coding sections upstream of the central polypurine tract (cPPT) do not yield better transduction efficiency, though it is unclear if the effect is due to viral production or integration impairment. We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.
Insights
Synthetic cytokine receptors called velocity receptors (VRs) enhance chimeric antigen receptor (CAR) T cell migration into solid tumors. Optimizing VR transduction improves CAR T cell therapy effectiveness for difficult-to-treat cancers.
Area of Science:
- Immunology
- Cellular Therapy
- Biotechnology
Background:
- Solid tumors present a significant challenge for chimeric antigen receptor (CAR) T cell therapy due to limited infiltration.
- Synthetic cytokine receptors, termed velocity receptors (VRs), have been developed to enhance CAR T cell motility by sensing inflammatory cytokines.
- These VR-modified CAR T cells can achieve a self-propelled, migratory state, improving penetration into dense tumor cores.
Purpose of the Study:
- To systematically evaluate factors influencing velocity receptor (VR) transduction for stable integration and expression.
- To optimize the development and functional studies of VR-CAR T cells for solid tumor cellular therapies.
Main Methods:
- Development of a dual-fluorescence reporter system for simultaneous monitoring of VR and CAR constructs.
- Evaluation of vector construct modifications and generation of standardized infectious unit (IFU) curves.
- Systematic assessment of lentiviral vector size reduction and its impact on transduction efficiency.
Main Results:
- Eliminating non-coding sections (cPPT) of lentiviral vectors did not improve transduction efficiency.
- A log-linear relationship was observed between viral dose and transduction efficiency for specific VRs.
- VR5αIL8 and VR5αTNFα demonstrated superior performance compared to VR5αIL5 and the native IL5 receptor (V5).
Conclusions:
- An optimized and reproducible framework for VR transduction has been established.
- These findings provide guidance for the future development of VR-CAR T cells.
- Enhanced CAR T cell migration is crucial for improving solid tumor treatment efficacy.

